The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MYC protein plays a critical role in cell growth and proliferation.
• MYC has a dual role in DNA Damage Response (DDR), promoting genomic instability while activating repair pathways.
• Understanding MYC's complex role in DDR is crucial for developing effective cancer therapies.

Purpose of the Study:

• To analyze how MYC inhibition impacts DNA Damage Response (DDR) pathway dependencies in cancer cells.
• To explore the potential of combining MYC inhibitors with DDR-targeting agents for synergistic anti-cancer effects.
• To summarize preclinical and early clinical evidence supporting this combination strategy.

Main Methods:

• Review of existing literature on MYC function in DDR.
• Analysis of how MYC inhibition affects DNA repair capacity and replication stress resistance.
• Exploration of combination strategies involving MYC inhibitors and various DDR modulators (e.g., PARP inhibitors, ATR/CHK1 inhibitors).

Main Results:

• MYC inhibition compromises cancer cells' DNA repair mechanisms and replication stress defenses.
• This creates a therapeutic vulnerability exploitable by combining MYC inhibitors with DDR-targeting agents.
• Preclinical studies show enhanced efficacy, and early clinical findings support this therapeutic approach.

Conclusions:

• MYC inhibition sensitizes cancer cells to DNA damage and replication stress.
• Combination therapy of MYC inhibitors with DDR-targeting agents offers a promising strategy for cancer treatment.
• Further clinical investigation is warranted to optimize these combination therapies.